On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.
| Automobile Components Industry | Consumer Discretionary Sector | Tao Ling CEO | NASDAQ (CM) Exchange | G67927122 CUSIP |
| CN Country | 117 Employees | - Last Dividend | 5 Aug 2025 Last Split | 27 Apr 2022 IPO Date |
Ostin Technology Group Co., Ltd., founded in 2010 and headquartered in Nanjing, China, is a key player in the electronics manufacturing industry specializing in the design, development, and manufacture of thin-film transistor liquid crystal display (TFT-LCD) modules and polarizers. The company's expertise lies in serving a broad range of applications within the consumer electronics sector, automotive industry, and commercial display markets. Ostin Technology Group takes pride in its direct sales approach to customers as well as its collaboration with customers' designated system integrators, ensuring tailored solutions that meet specific display needs.
Ostin Technology Group Co., Ltd. offers a wide array of display modules and related products catered to diverse markets: